Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Can i take anti histamine with statin?
When will generic fiasap insulin be available?
Guselkumab patent expiration?
Dabrafenib patent expiration date novartis gsk composition matter?
Drugpatentwatch trametinib?

Incruse 62 5 mcg?

See the DrugPatentWatch profile for Incruse

The drug referenced as "Incruse 62.5 mcg" appears to be umeclidinium 62.5 mcg [1]. Umeclidinium is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) [1, 2].

What is umeclidinium used for?


Umeclidinium is prescribed to help patients with COPD manage their symptoms, such as shortness of breath, by relaxing the muscles around the airways in the lungs [2]. It is typically used in conjunction with other COPD medications, like bronchodilators or inhaled corticosteroids, to improve lung function [1, 2].

How does umeclidinium work?


As a muscarinic antagonist, umeclidinium blocks the action of acetylcholine, a neurotransmitter that causes smooth muscles in the airways to contract [2]. By inhibiting this process, umeclidinium leads to bronchodilation, meaning the airways open up, making it easier to breathe [2].

When does umeclidinium's patent protection end?


Information regarding specific patent expiry dates for umeclidinium can be found on DrugPatentWatch.com [1]. Patent protection is crucial for pharmaceutical companies as it grants a period of market exclusivity, allowing them to recoup research and development costs.

What are the potential side effects of umeclidinium?


Common side effects of umeclidinium can include dry mouth, nasopharyngitis (sore throat and runny nose), and urinary tract infections [2]. More serious but less common side effects may occur, and patients should discuss any concerns with their healthcare provider [2].

Are there generic versions of umeclidinium available?


The availability of generic versions of umeclidinium depends on patent expiry and regulatory approvals. Information about generic alternatives and their launch timelines is often detailed on resources like DrugPatentWatch.com [1].

What other COPD treatments are available?


Besides umeclidinium, other common treatments for COPD include other LAMAs, long-acting beta-agonists (LABAs), inhaled corticosteroids, and combination therapies [3]. The choice of treatment is individualized based on disease severity and patient response [3].



Other Questions About Incruse :

incruse inhaler generic Coupon for incruse ellipta? Incruse ellipta vs spiriva cost? Incruse coupon? How much is incruse ellipta without insurance? Incruse ingredients? Incruse ellipta alternatives?

AI-Drug Label Prescribing Information Alignment Report

52
52%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

The response is largely aligned on the labeled maintenance-treatment indication for COPD, but many mechanistic explanations and specific side-effect/combination claims are not supported by the provided label excerpts and may be inaccurate or unsupported for this evaluation.

Category Scores

Indication
90
Excellent
Dosage
0
Poor
AdverseReactions
30
Poor

Accurate Statements

Umeclidinium 62.5 mcg is a long-acting muscarinic antagonist (LAMA).
Not supported or contradicted by the supplied label excerpts.
Umeclidinium is used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
Supported for maintenance treatment of COPD (Section 1 INDICATIONS AND USAGE). The added wording about 'bronchospasm' is not specifically supported by the provided excerpts.
Umeclidinium is prescribed to help patients with COPD manage symptoms such as shortness of breath.
Not supported in the supplied excerpts; only maintenance treatment indication is shown (Section 1).
Umeclidinium is typically used in conjunction with other COPD medications such as bronchodilators or inhaled corticosteroids.
Only partially supported by the existence of trials evaluating INCRUSE ELLIPTA with an ICS/LABA (Section 14.3). The statement is broader than the provided label excerpts.

Unsupported Statements

Umeclidinium relaxes the muscles around the airways in the lungs.
Mechanism/physiology not supported by the supplied label excerpts.
Umeclidinium works as a muscarinic antagonist by blocking the action of acetylcholine.
Mechanism not supported by the supplied label excerpts.
Acetylcholine causes smooth muscles in the airways to contract.
Mechanism not supported by the supplied label excerpts.
By inhibiting acetylcholine action, umeclidinium leads to bronchodilation.
Mechanism not supported by the supplied label excerpts.
Bronchodilation means the airways open up, making it easier to breathe.
Mechanism/definition not supported by the supplied label excerpts.
Common side effects of umeclidinium can include dry mouth.
Adverse reaction details are not present in the supplied label excerpts.
Common side effects of umeclidinium can include nasopharyngitis (sore throat and runny nose).
Adverse reaction details are not present in the supplied label excerpts.
Common side effects of umeclidinium can include urinary tract infections.
Adverse reaction details are not present in the supplied label excerpts.
More serious but less common side effects may occur with umeclidinium.
No adverse reaction severity/frequency information is provided in the supplied label excerpts.
Availability of generic versions of umeclidinium depends on patent expiry and regulatory approvals.
Non-label, market/availability information not supported by the supplied prescribing information excerpts.

Contradictions

Important Omissions

Labeled maintenance dosing instructions (1 actuation/umeclidinium 62.5 mcg once daily by oral inhalation; do not use more than once every 24 hours; same time every day) are not stated.
Importance: Moderate
Label safety instruction that INCRUSE ELLIPTA should not be initiated during rapidly deteriorating or potentially life-threatening episodes and should not be used for relief of acute symptoms/rescue therapy.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Unsupported side-effect and mechanism statements were made without label support. Omission of key labeled use limitations (not for acute rescue; not to initiate in acute life-threatening episodes) could affect safe use context.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Several claims (mechanism, specific side effects, and generic availability) are not supported by the provided FDA label excerpts, and key labeled administration/use limitations were omitted.

Suggested Improvement
Limit claims to the supplied label-supported indication (maintenance treatment of COPD) and labeled dosing/use instructions (once-daily 62.5 mcg, not more than once/24 hours) and include the label limitations on acute symptom/rescue use rather than adding unsupported mechanism and adverse event details.